Reduced capital costs, faster installation, and the smaller footprint of single-use systems as compared to stainless steel
equipment have helped make in-house production feasible for many biotechnology companies. These benefits also provide significant
cost-savings for large drug companies and contract manufacturers.
Hélène Pora, PhD, is the marketing director at Pall Life Sciences, Pall France, Saint Germain-en-Laye Cedex-France, +22.214.171.124.32.20, email@example.com
1. BioPlan Associates. Third annual report on biopharmaceutical manufacturing capacity and production. 2005 Jun. Cited in
Brown A. Chem Processing. Disposable equipment makes lasting gains. 2006.